Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
Anticoagulation during percutaneous coronary intervention is critical to prevent abrupt and subacute closure. Although heparin has been the primary anticoagulant used for this purpose, a number of new drugs are now available. Low molecular weight heparin (LMWH) offers some advantages over unfractionated heparin, and clinical trials have shown its superiority. However, the longer half-life and lack of monitoring of LMWH make its use more difficult. The direct thrombin inhibitors also have been shown to have advantages in the treatment of patients with heparin-induced thrombocytopenia.
French
Matthew H
MH
Section of Cardiology, University of Chicago, Chicago, IL, USA.
Faxon
David P
DP
D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000925:Anticoagulants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D000077425:Fondaparinux; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006629:Hirudins; D010446:Peptide Fragments; D011134:Polysaccharides; D011994:Recombinant Proteins; D006493:Heparin; D000077425:Fondaparinux; C074619:bivalirudin